Skip to Main Content

Paper Details

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Alzheimers Res Ther
345
2021
AD, AD dementia, Alzheimer's Disease, Alzheimer's disease, BAN2401, BAN2401-G000-, CDR, Dementia, IgG1 monoclonal antibody, Lecanemab, amyloid, amyloid beta (A), anti-A protofibril, cognitive impairment, edema, effusion, lecanemab, oligomers

Datasets

Release 1.2